Results 41 to 50 of about 28,895 (261)

How Cannabinol Is Utilized in Japan, a Country with Strict Cannabis Regulations—Its Purposes, Medical Effects, Adverse Events, and Dependence

Integrative Medicine Reports
Introduction: Cannabinol (CBN) was discovered in 1896, but its commercial use did not take off until recently, and there have been few studies on its use, safety, and efficacy.
Yuji Masataka, Futaba Umemura, Akihiko Nagamine, Naoko Miki, Yoshiyuki Akahoshi, Toshihiko Matsumoto, Ichiro Takumi   +6 more
doaj   +1 more source

Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis

Molecules, 2021
Cannabis sativa is one of the oldest medicinal plants in the world. It was introduced into western medicine during the early 19th century. It contains a complex mixture of secondary metabolites, including cannabinoids and non-cannabinoid-type ...
Mohamed M. Radwan, Suman Chandra, Shahbaz Gul, Mahmoud A. ElSohly   +3 more
doaj   +1 more source

Mobile EEG examination of putative biomarkers of mental health in individuals that use cannabis

NPP-Digital Psychiatry and Neuroscience
Healthy individuals that use cannabis are at greater risk of developing mental health conditions than those that do not use cannabis. Here, using mobile electroencephalography (EEG) in controlled laboratory settings, we examined two putative biomarkers ...
Conor H. Murray, Kaihan Danesh, Ziva D. Cooper   +2 more
doaj   +1 more source

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Associations of U.S. state-level COVID-19 policies intensity with cannabis sharing behaviors in 2020

Harm Reduction Journal
Background Cannabis use before the COVID-19 pandemic for many involved sharing prepared cannabis for inhalation, practices that were less prevalent during the pandemic. State-level COVID-19 containment policies may have influenced this decrease.
Ryan D. Assaf, Rita Hamad, Marjan Javanbakht, Onyebuchi A. Arah, Steven J. Shoptaw, Ziva D. Cooper, Pamina M. Gorbach   +6 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

Cannabinoids in immune system-related diseases: From bench to clinic

Chinese Medical Journal
. As a psychoactive drug, marijuana is used for recreational purposes. Given its addictive nature and the serious damage it causes to both individual health and social stability, marijuana has been banned in most countries worldwide.
Wenyu Zhang, Buzhuo Chen, Yanting Cao, Wangrui Lei, Huadong Zhao, Yang Yang, Jiayou Tang, Xiangxiang Pan   +7 more
doaj   +1 more source

The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation

Molecules, 2021
Significant growth of interest in cannabis (Cannabis sativa L.), especially its natural anti-inflammatory and antioxidative properties, has been observed recently.
Michał Graczyk, Agata Anna Lewandowska, Tomasz Dzierżanowski   +2 more
doaj   +1 more source